A STING agonist preconditions against ischaemic stroke via an adaptive antiviral Type 1 interferon response
Authors:
Open Access
- 24 May 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 4 (3) , fcac133
Abstract
Converging lines of inquiry have highlighted the importance of the Type I antiviral response not only in defending against viruses but also in preconditioning the brain against ischaemic stroke. Despite this understanding, treatments that foster brain resilience by driving antiviral interferon responses have yet to be developed for human use. Studies from our laboratory showed that tilorone, the first human antiviral immunomodulatory agent to be developed, robustly preconditioned against stroke in mice and rats. Tilorone is a DNA intercalator; therefore, we hypothesized that it stabilizes cytosolic DNA (released from the mitochondria or the nucleus), thereby activating cyclic GMP–AMP synthase, a homeostatic DNA sensor, and its downstream pathway. This pathway involves stimulator of interferon genes (STING), tank-binding kinase 1 (TBK1), and interferon regulatory protein-3 and culminates in a protective Type I interferon response. We tested this hypothesis by examining the ability of structurally diverse small-molecule agonists of STING to protect against oxygen/glucose deprivation in vitro in mouse cortical cultures and in vivo against transient ischaemia in mice. The STING agonists significantly reduced cell death both in vitro and in vivo but failed to do so in STING knockout mice. As expected, STING agonist-induced protection was associated with the induction of interferon related genes and the effects could be abrogated in vitro by a TBK1 inhibitor. Taken together, these findings in mice identify STING as a therapeutic target for preconditioning the brain against ischaemic stroke in vitro and in vivo. Moreover, they suggest that clinically approved STING agonists such as Ganciclovir or α-Mangostin are candidate drugs that could be tested in humans as a prophylactic treatment to alleviate brain injury associated with ischaemic stroke.Keywords
Funding Information
- Dr Miriam and Sheldon G. Adelson Foundation
This publication has 41 references indexed in Scilit:
- The Innate Immune DNA Sensor cGAS Produces a Noncanonical Cyclic Dinucleotide that Activates Human STINGCell Reports, 2013
- Toll-Like Receptor 7 Preconditioning Induces Robust Neuroprotection Against Stroke by a Novel Type I Interferon-Mediated MechanismStroke, 2012
- STING Specifies IRF3 Phosphorylation by TBK1 in the Cytosolic DNA Signaling PathwayScience Signaling, 2012
- LPS preconditioning redirects TLR signaling following stroke: TRIF-IRF3 plays a seminal role in mediating tolerance to ischemic injuryJournal of Neuroinflammation, 2011
- Multiple Preconditioning Paradigms Converge on Interferon Regulatory Factor-Dependent Signaling to Promote Tolerance to Ischemic Brain InjuryThe Journal of Neuroscience, 2011
- Systemic Lipopolysaccharide Protects the Brain from Ischemic Injury by Reprogramming the Response of the Brain to Stroke: A Critical Role for IRF3Journal of Neuroscience, 2009
- Use of the Pharmacological Inhibitor BX795 to Study the Regulation and Physiological Roles of TBK1 and IκB Kinase ϵJournal of Biological Chemistry, 2009
- Small Molecule Activation of Adaptive Gene ExpressionAnnals of the New York Academy of Sciences, 2008
- Toll-Like Receptor 9: A New Target of Ischemic Preconditioning in the BrainJournal of Cerebral Blood Flow & Metabolism, 2008
- Mode of tilorone hydrochloride interaction to DNA and polydeoxyribonucleotidesFEBS Letters, 1972